Insider Buying Continues as KORU’s CEO Adds Shares
After a modest uptick in share price, CEO Tharby Linda M purchased 1,191 common shares on May 15, 2026. The deal, priced at $4.00 per share—virtually the same as the market close—adds to a pattern of incremental purchases by the company’s top executive. In the days leading up to the trade, Tharby added 13,977 shares (buy) and sold 7,326 shares (sell) at $3.94, keeping her total holdings above 620,000 shares. Her recent buying spree is in line with the broader insider activity this quarter, where other senior officers—COO Christopher Pazdan and CFO Thomas Edward Adams—also took small, balanced positions.
Implications for Investors
The transaction is largely perfunctory from a market‑impact standpoint. The shares represent a small fraction of KORU’s outstanding equity (market cap $179 million, 52‑week high $6.61), and the trades occurred at round‑number prices, suggesting a lack of tactical timing. However, the consistency of CEO purchases—especially following a sizable sell in April—can be interpreted as a signal of confidence in the company’s near‑term prospects. KORU’s stock has seen a 3.9 % weekly gain and a 47 % yearly rise, bolstered by a strong product pipeline in subcutaneous infusion devices. Insider accumulation may reinforce that narrative for risk‑averse investors, while the negative P/E of –76.2 highlights the company’s valuation still being heavily weighted toward future growth rather than current earnings.
What the Pattern Reveals About Tharby’s Strategy
Tharby’s historical trades show a “buy‑then‑sell‑then‑buy” rhythm. In March she bought 15,968 shares at $0.00 (indicative of a vesting event) and sold 5,756 shares at $4.28, a price roughly 7 % above the May close. In April she sold 23,587 shares at $2.20, the lowest price in that window, before buying back a smaller block the following day. These moves suggest she is willing to liquidate holdings when prices dip to secure gains, but she also re‑acquires shares when the market stabilizes—an approach consistent with a long‑term, patient‑investment mindset. Her cumulative post‑transaction holdings have steadily climbed, from 15,968 in March to over 1 million by April 21, indicating a long‑term stake that aligns with the company’s strategic direction.
Broader Context and Outlook
KORU’s insider transactions appear to be routine vesting and tax‑related adjustments rather than opportunistic trades. The company’s recent earnings and product developments—particularly the focus on immunoglobulin delivery for chronic conditions—provide a solid growth thesis. For investors, the CEO’s ongoing purchases add a layer of credibility to management’s belief in the firm’s trajectory, though the negative P/E and modest liquidity mean caution is still warranted. As KORU continues to scale its device portfolio, insider confidence could serve as a quiet catalyst for further share price appreciation, provided the company maintains its operational momentum.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-05-15 | Tharby Linda M (Chief Executive Officer) | Buy | 1,191.00 | 1,191.00 | Common Stock |
